💥 Zero Bullshit
Chapitre 02

Looks like I picked the wrong week to quit drinking.

Because all told, Ÿnsect will have raised more than €500M in 5 years. Or €435M. Or… actually, nobody knows.

In truth, we shouldn’t care. In fact, if start-ups founded by women raise 3 to 5 times less, maybe it’s not only because VCs don’t trust them out of plain everyday sexism, but because female founders don’t get into dick-measuring contests to make it into Maddyness, a French start-up news site, and show their mates.

And even if it’s put (a little) crudely, it’s far from trivial. Because these funding rounds delight journalists and politicians, who relay them without ever checking, feeding the contest for whoever has the biggest horn (on their unicorn).

Besides the fact that unicorn status is sometimes reached in dollars (Swile, a French employee-benefits start-up, for example), the amounts raised cover very different realities. They lump together equity, loans, convertible bonds and grants, when these obviously don’t have the same impact on the company.

That’s what makes a gap of more than €100M between the articles about Ÿnsect’s funding rounds and the accounting reality.

In 2014, Ÿnsect held its first funding round, a €1.8M Series A with Emertec Gestion and Demeter Partners2, to open its first plant in Dole, in eastern France. Then came a $15.2M Series B with Future Positive Capital and Bpifrance, France’s public investment bank.3

When plans for a plant in Amiens, in northern France, emerged at the end of 2017, Ÿnsect went looking for a lot of money. The Series C was led by Astanor Ventures, a VC specialising in agritech. $148M was announced in 2019, topped up with €372M in 2020, according to a company press release.4

The figures were picked up everywhere.
What was picked up less is why a top-up was added a year later.

The Amiens project was badly hit by Covid-19, which caused many delays. So losses, which would only get worse. Just like the delays.

Ÿnsect used the flood of cash to buy Protifarm in the Netherlands, renamed Ÿnsect NL. Cost of the deal: €14.25M.

Time went by… and Amiens, which was supposed to be up and running by the end of 2021, still hadn’t opened.

In early 2022, Ÿnsect wanted to raise €250M in a Series D, except… Rates were rising, VCs were cooling off, mega-rounds were getting rare… and Ÿnsect’s targets were very, very far from being met. At the Series C, the company was projecting 5-year revenue of €500M5, when it actually came to just €17.8M that year. Which, to this day, is still its record year.6

The problem is that Ÿnsect doesn’t have much time. On top of inflation, the war in Ukraine was pushing up the cost of cereals and energy, sending the start-up’s costs through the roof. Its existing shareholders had to cough up €50M in June to avoid the worst.

From 2023, the company was again hunting for €250M while working on a cost-cutting plan, and the Amiens plant still wasn’t ready. It would only open in early 2024. Unsurprisingly, investors weren’t exactly raring to go.

A €160M Series D was eventually announced in the press7. A figure leaked off the record: a €600M valuation for the big bug that was calling itself a unicorn not long before. Everyone could smell the con coming… Especially when, at the same time, the 360-strong workforce had to shed 38 jobs.

Except that, in reality, that €160M was the €50M bridge from June 2022, plus €107M in convertible bonds. In April 2023, the shareholders’ meeting had voted to allow the issue of up to €200M in convertibles.

Convertibles had already been issued for €51M in 2022.

That makes more than €232M in debt8 and nearly €9M in interest.
It was €125M in 2022.
€33M in 2021.